Elisabeth A. Lasater

2.1k citations

21 papers · 963 indexed · h-index 12

Co-authors: Neil P. Shah Catherine C. Smith Kimberly C. Lin Lauren E. Damon Stefan Knapp Susanne Müller P. Filippakopoulos Lisa Wodicka
Topics: Chronic Lymphocytic Leukemia Research (14 papers)Acute Myeloid Leukemia Research (12 papers)Chronic Myeloid Leukemia Treatments (10 papers)
Cited by: Hematology Genetics Molecular Biology
Journals: Proceedings of the National Academy of Sciences Journal of Clinical Investigation Blood
Partner nations: United States United Kingdom Hong Kong

In The Last Decade

Elisabeth A. Lasater

21 papers receiving 956 citations

Peers

Countries citing papers authored by Elisabeth A. Lasater

Since Specialization

Citations

This map shows the geographic impact of Elisabeth A. Lasater's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth A. Lasater with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth A. Lasater more than expected).

Fields of papers citing papers by Elisabeth A. Lasater

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabeth A. Lasater. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth A. Lasater. The network helps show where Elisabeth A. Lasater may publish in the future.

Co-authorship network of co-authors of Elisabeth A. Lasater

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth A. Lasater. A scholar is included among the top collaborators of Elisabeth A. Lasater based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth A. Lasater. Elisabeth A. Lasater is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas 2023 ·Blood ·Stephen J. Schuster,Ling‐Yuh Huw,Christopher R. Bolen,Victor Maximov,Andrew G. Polson,Katerina Hatzi,Elisabeth A. Lasater,Sarit Assouline,Nancy L. Bartlett,Lihua E. Budde,Matthew J. Matasar,Hartmut Koeppen,Emily Piccione,(unknown),Michael C. Wei,Shen Yin,Elicia Penuel	34
2	Novel CD20 Mutations As a Mechanism of Resistance to CD20-CD3 Targeted Therapies in Non-Hodgkin's Lymphoma 2023 ·Blood ·Victor Maximov,Christopher R. Bolen,Andrew G. Polson,Elicia Penuel,Elisabeth A. Lasater	1
3	A Novel Transcriptomic Classifier for AML Is Highly Associated with Drug Sensitivity 2021 ·Blood ·Habib Hamidi,Christopher R. Bolen,Elisabeth A. Lasater,Diana Dunshee,Elizabeth A. Punnoose,Monique Dail	1
4	Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models 2020 ·Haematologica ·Raghuveer Singh Mali,Qi Zhang,RosaAnna DeFilippis,Antonio Cavazos,Vinitha M. Kuruvilla,(unknown),Vidhi Mody,Edna F. Choo,Monique Dail,Neil P. Shah,Marina Konopleva,Deepak Sampath,Elisabeth A. Lasater	97
5	Abstract B052: FLT3-ITD activation mediates resistance to the BCL-2 selective antagonist, venetoclax, in FLT3-ITD mutant AML models 2018 ·Molecular Cancer Therapeutics ·Raghuveer Singh Mali,Elisabeth A. Lasater,Kelly Doyle,(unknown),Erwin R. Boghaert,Andrew J. Souers,Joel Johansson,Deepak Sampath	4
6	Resistance of Natural Killer and T Cells to Venetoclax Allows for Combination Treatment with Cancer Immunotherapy Agents 2018 ·Blood ·Elisabeth A. Lasater,An D,Luciana Burton,Yijin Li,Erin Williams,Jason Oeh,Luciana Molinero,Elicia Penuel,Deepak Sampath,Monique Dail,Marcia Belvin,Teiko Sumiyoshi,Elizabeth A. Punnoose,Jeffrey M. Venstrom,Aparna Raval	3
7	FLT3-ITD Activation Mediates Resistance to the BCL-2 Selective Antagonist, Venetoclax, in FLT3-ITD Mutant AML Models 2017 ·Blood ·Raghuveer Singh Mali,Elisabeth A. Lasater,Kelly Doyle,(unknown),Erwin R. Boghaert,Andrew J. Souers,Joel Johansson,Deepak Sampath	17
8	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia 2016 ·JCI Insight ·Katherine A. Minson,Catherine C. Smith,Deborah DeRyckere,(unknown),Alisa B. Lee‐Sherick,(unknown),Elisabeth A. Lasater,(unknown),Michael A. Stashko,Weihe Zhang,Craig T. Jordan,Dmitri Kireev,Xiaodong Wang,Stephen V. Frye,H. Shelton Earp,Neil P. Shah,Douglas K. Graham	61
9	Dual kinase-bromodomain inhibitors for rationally designed polypharmacology 2014 ·Nature Chemical Biology ·Pietro Ciceri,Susanne Müller,Alison O’Mahony,O. Fedorov,P. Filippakopoulos,Jeremy P. Hunt,Elisabeth A. Lasater,Gabriel Pallares,S. Picaud,Christopher Wells,Sarah Martin,Lisa Wodicka,Neil P. Shah,Daniel K. Treiber,Stefan Knapp	261
10	Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy 2014 ·eLife ·(unknown),Michael S. Lopez,Elisabeth A. Lasater,Kimberly C. Lin,Bai‐Liang He,(unknown),Catherine C. Smith,Neil P. Shah,Kevan M. Shokat	44
11	Crenolanib is a selective type I pan-FLT3 inhibitor 2014 ·Proceedings of the National Academy of Sciences ·Catherine C. Smith,Elisabeth A. Lasater,Kimberly C. Lin,Qi Wang,Melissa Q. McCreery,(unknown),Lauren E. Damon,Alexander E. Perl,Grace R. Jeschke,Mayumi Sugita,Martin Carroll,Scott C. Kogan,John Kuriyan,Neil P. Shah	172
12	MEK-Dependent Negative Feedback Underlies BCR–ABL-Mediated Oncogene Addiction 2013 ·Cancer Discovery ·(unknown),Elisabeth A. Lasater,Cheryl Tajon,Juan A. Osés-Prieto,Young‐wook Jun,Barry S. Taylor,Alma L. Burlingame,Charles S. Craik,Neil P. Shah	27
13	Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML) 2013 ·Blood ·Catherine C. Smith,Kimberly C. Lin,Elisabeth A. Lasater,(unknown),Lauren E. Damon,Andrew Kasarskis,Ali Bashir,Matthew Pendleton,Robert Sebra,Alexander E. Perl,Mai H. Le,Chao Zhang,Brian L. West,Neil P. Shah	6
14	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD 2013 ·Blood ·Catherine C. Smith,Elisabeth A. Lasater,Xiaotian Zhu,Kimberly C. Lin,(unknown),Lauren E. Damon,Sara Salerno,Neil P. Shah	101
15	Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220 2012 ·Blood ·Catherine C. Smith,(unknown),Elisabeth A. Lasater,Amy L. Paguirigan,Kimberly C. Lin,(unknown),Sara Salerno,Lauren E. Damon,Mark J. Levis,Alexander E. Perl,Kevin Travers,Andrew Kasarskis,Jerald P. Radich,Neil P. Shah	4
16	Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants 2012 ·Blood ·Catherine C. Smith,Elisabeth A. Lasater,Melissa Q. McCreery,Kimberly C. Lin,(unknown),Lauren E. Damon,Alexander E. Perl,Grace R. Jeschke,Mayumi Sugita,Martin Carroll,Scott C. Kogan,Neil P. Shah	14
17	Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations 2011 ·Blood ·Warren Fiskus,Catherine C. Smith,Jacqueline Smith,Scott Wise,Elisabeth A. Lasater,Lauren E. Damon,Sara Salerno,(unknown),Ruben Reyes,Siddhartha Ganguly,Mark S. Berger,(unknown),Joseph P. McGuirk,Neil P. Shah,Kapil N. Bhalla	3
18	PLX3397 Is An Investigational Selective FLT3 Inhibitor That Retains Activity Against the Clinically-Relevant FLT3-ITD/F691L “Gatekeeper” Mutation in Vitro 2011 ·Blood ·Catherine C. Smith,Alexander E. Perl,Elisabeth A. Lasater,Chao Zhang,Grace R. Jeschke,Lauren E. Damon,Martin Carroll,Neil P. Shah	8
19	Genetic and cellular evidence of vascular inflammation in neurofibromin-deficient mice and humans 2010 ·Journal of Clinical Investigation ·Elisabeth A. Lasater,Fang Li,Waylan Bessler,Myka L. Estes,Sasidhar Vemula,Cynthia M. Hingtgen,Mary C. Dinauer,Reuben Kapur,Simon J. Conway,David A. Ingram	58
20	Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway 2008 ·Human Molecular Genetics ·Elisabeth A. Lasater,Waylan Bessler,Laura E. Mead,(unknown),D. Wade Clapp,Simon J. Conway,D A Ingram,Fankang Li	44

About Elisabeth A. Lasater

Elisabeth A. Lasater is a scholar working on Hematology, Genetics and Oncology, having authored 21 papers that have together received 963 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (14 papers), Acute Myeloid Leukemia Research (12 papers) and Chronic Myeloid Leukemia Treatments (10 papers). The work is most often cited by research in Hematology (559 citations), Genetics (222 citations) and Molecular Biology (522 citations). Elisabeth A. Lasater has collaborated with scholars based in United States, United Kingdom and Hong Kong. Frequent co-authors include Neil P. Shah, Catherine C. Smith, Kimberly C. Lin, Lauren E. Damon, Stefan Knapp, Susanne Müller, P. Filippakopoulos, Lisa Wodicka, Alison O’Mahony and S. Picaud. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact